Figure 6
IL-17A production from PBMC of healthy donors and RA patients and effect of JNJ-54271074 on IL-17A and IL-22 production from RA PBMCs.
(A-B) Comparison of accumulated IL-17A after 3 days of culture. PBMCs were stimulated with anti-CD3/anti-CD28 only or anti-CD3/anti-CD28 plus IL-1β and IL-23 for 3 days, and supernatants were analyzed for IL-17A and IL-22 using MSD or ELISA. Each symbol represents mean value of duplicate assays from individual healthy donors (n = 5) or RA patients (n = 5). (C-D) Representative dose response curves of IL-17A and IL-22 for JNJ-54271074 in RA PBMC for one of five patients. PBMCs were stimulated with anti-CD3/anti-CD28 plus IL-1β and IL-23 for 3 days in the presence of titrated JNJ-54271074. Data are presented as mean ± SD of duplicate assays. The statistical analyses were performed using unpaired t test with Welch’s correction, *P < 0.05; **P < 0.01; ***P < 0.005.
